Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI Regimen Versus VIT Regimen in Relapsed and Refractory Pediatric Rhabdomyosarcoma
NCT05457829Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in rhabdomyosarcoma (RMS) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 weeks. Started Dec 2023; status: recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT05457829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457829.